What is HC Wainwright’s Estimate for ARQT Q3 Earnings?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) – Analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for Arcutis Biotherapeutics in a report released on Thursday, August 6th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $0.17 per share for the quarter, up from their prior forecast of $0.06. The consensus estimate for Arcutis Biotherapeutics’ current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics’ Q4 2026 earnings at $0.25 EPS, FY2026 earnings at $0.44 EPS, FY2027 earnings at $1.00 EPS, FY2028 earnings at $1.66 EPS, FY2029 earnings at $2.07 EPS and FY2030 earnings at $2.36 EPS.

ARQT has been the subject of several other research reports. Needham & Company LLC raised their price objective on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Guggenheim upped their target price on shares of Arcutis Biotherapeutics from $35.00 to $38.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Weiss Ratings upgraded shares of Arcutis Biotherapeutics from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, August 6th. Morgan Stanley increased their target price on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Finally, Wall Street Zen upgraded shares of Arcutis Biotherapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Six analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, Arcutis Biotherapeutics presently has an average rating of “Moderate Buy” and an average target price of $35.57.

Arcutis Biotherapeutics Price Performance

Shares of NASDAQ ARQT opened at $26.23 on Monday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.67 and a current ratio of 2.92. Arcutis Biotherapeutics has a one year low of $14.08 and a one year high of $31.77. The firm has a market capitalization of $3.30 billion, a P/E ratio of 124.91 and a beta of 1.49. The company’s fifty day moving average is $26.25 and its two-hundred day moving average is $24.68.

Arcutis Biotherapeutics (NASDAQ:ARQT) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.05. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%.The firm had revenue of $129.86 million during the quarter, compared to analysts’ expectations of $118.85 million.

Institutional Investors Weigh In On Arcutis Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. SBI Securities Co. Ltd. increased its position in Arcutis Biotherapeutics by 325.4% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,089 shares of the company’s stock worth $32,000 after buying an additional 833 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in shares of Arcutis Biotherapeutics in the fourth quarter valued at $35,000. EverSource Wealth Advisors LLC lifted its position in shares of Arcutis Biotherapeutics by 124.0% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,261 shares of the company’s stock valued at $37,000 after acquiring an additional 698 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Arcutis Biotherapeutics by 209.0% in the fourth quarter. NewEdge Advisors LLC now owns 1,545 shares of the company’s stock valued at $45,000 after acquiring an additional 1,045 shares in the last quarter. Finally, Truvestments Capital LLC boosted its stake in shares of Arcutis Biotherapeutics by 114.2% during the fourth quarter. Truvestments Capital LLC now owns 3,012 shares of the company’s stock valued at $87,000 after acquiring an additional 1,606 shares during the last quarter.

Insider Buying and Selling at Arcutis Biotherapeutics

In other news, Director Howard G. Welgus sold 4,096 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.41, for a total value of $99,983.36. Following the sale, the director directly owned 38,378 shares in the company, valued at $936,806.98. This represents a 9.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Todd Watanabe sold 4,375 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $26.12, for a total transaction of $114,275.00. Following the completion of the sale, the insider owned 717,203 shares in the company, valued at $18,733,342.36. This represents a 0.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,237 shares of company stock valued at $408,214 in the last quarter. Insiders own 9.40% of the company’s stock.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.